Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Why the future of marijuana legalization remains hazy despite high public support 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
Trump Nominates Cameron Hamilton to Lead FEMA After Previous Ouster 
EU Approves New Sanctions on Israeli Settlers and Hamas Leaders 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Trump-Xi China Summit 2026: Trade Tensions, Taiwan, and Iran Take Center Stage 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
